RT Journal Article
SR Electronic
T1 Mitogen activated protein kinases as targets for development of novel anti-inflammatory drugs
JF Annals of the Rheumatic Diseases
JO Ann Rheum Dis
FD BMJ Publishing Group Ltd and European League Against Rheumatism
SP ii62
OP ii64
DO 10.1136/ard.2004.028274
VO 63
IS suppl 2
A1 M Karin
YR 2004
UL http://ard.bmj.com/content/63/suppl_2/ii62.abstract
AB Given the prevalence and debilitating nature of chronic inflammatory diseases there is a never ending quest for identification of novel targets for the rational development of anti-inflammatory drugs. Although the major signalling pathway that controls inflammation associated gene expression is the one leading to activation of transcription factor NF-κB, considerable attention has also been given to mitogen activated protein kinases (MAPKs) as likely targets for development of novel anti-inflammatory therapeutics. Indeed, inhibitors targeting these pathways have been developed and preliminary preclinical data suggest that they exhibit anti-inflammatory activity. This report focuses on the possible mechanisms through which such inhibitors may interfere with inflammation and discusses the pros and cons of targeting MAPKs in the treatment of chronic inflammatory disease.